How Long Does Clinical Trial Approval Take in China for Foreign Pharma?

1. Overview of the Clinical Trial Approval Timeline

For foreign pharmaceutical companies planning clinical trials in China, understanding the approval timeline is critical for trial planning, budget allocation, and global development program synchronization. China’s clinical trial approval process has undergone significant reform since 2015, with the most dramatic acceleration occurring after the 2017 ICH membership and the 2018 Drug Administration Law revisions.

The total timeline from IND submission to first patient enrolled can be broken down into four distinct phases: pre-submission activities, CDE regulatory review, ethics committee approval, and site initiation. Each phase has its own timeline and requirements. The following table summarizes the typical timelines for different scenarios:

2. Detailed Breakdown of Each Phase

2.1 Pre-Submission Phase (1-3 months)

Before submitting the formal IND application, most foreign sponsors benefit from engaging with the CDE through the pre-submission meeting process. This voluntary step allows sponsors to discuss trial design, CMC strategy, and data requirements with CDE reviewers and obtain preliminary feedback. The pre-submission process includes:

• Pre-submission meeting application: Submit a meeting request with a briefing document describing the drug, proposed trial design, and specific questions for CDE feedback. The CDE aims to schedule meetings within 30-45 days of receiving the request
• Pre-submission meeting: A 60-90 minute meeting (typically conducted virtually) with CDE reviewers. The meeting provides non-binding guidance on the acceptability of the proposed trial design and data package
• Meeting minutes: The CDE issues formal meeting minutes within 15-30 days of the meeting, documenting their recommendations and concerns
• Dossier finalization: Based on CDE feedback, the sponsor finalizes the IND dossier for submission. This may take 2-4 weeks depending on the extent of changes required

While the pre-submission meeting is optional, it is strongly recommended for foreign sponsors submitting their first IND in China. The meeting can identify potential issues early, saving months of review time later, and helps build the relationship with the CDE review team.

2.2 CDE Regulatory Review (2-6 months)

The formal CDE review period is the most heavily regulated phase. Key milestones include:

• Submission acceptance (3-5 business days): The CDE conducts a preliminary completeness check upon receiving the IND dossier. If the dossier passes, an application number is assigned and the formal review clock starts
• Technical review (60 working days standard): The CDE’s statutory review period is 60 working days (approximately 3 calendar months). During this period, the CDE assigns primary and secondary reviewers who evaluate the entire dossier. The review covers CMC quality, preclinical safety, clinical trial design, and overall benefit-risk assessment
• Silent approval mechanism: If the CDE does not issue any deficiency letters within 60 working days of accepting a complete submission, the sponsor is deemed to have received IND approval and may proceed with the trial. This “silent approval” mechanism provides regulatory certainty and has significantly reduced approval timelines compared to the pre-reform system, which could take 12-18 months
• Deficiency letters (clock stops): If the CDE identifies issues, it issues a deficiency letter requesting additional data or clarifications. The review clock stops while the sponsor prepares responses. Typical response time is 30-90 days, depending on the complexity of the questions. Common deficiency areas include CMC quality concerns (especially for biologics), inadequate preclinical safety data, unclear clinical design, and insufficient justification for dose selection
• Supplemental review (20-30 working days): After the sponsor submits responses, the CDE has 20-30 working days to review the supplemental materials and issue a final decision. Multiple rounds of questions are possible but uncommon for standard IND applications

The CDE has established specialized review teams for different drug categories. Oncology drugs are reviewed by the oncology team, biologics by the biological products team, and cell/gene therapies by the advanced therapy team. Each team has different expertise and may apply different review standards. Understanding which team will review a specific application helps sponsors prepare the dossier appropriately.

2.3 Ethics Committee Approval (1-3 months)

After CDE approval (or in parallel, for some trial types), the sponsor must obtain ethics committee (Institutional Review Board / IRB) approval from each participating trial site. China has been moving toward a centralized ethics review system:

• Lead IRB review: For multi-center trials, the lead site’s IRB provides primary review. Since the 2017 pilot program and subsequent nationwide implementation, participating sites generally accept the lead IRB’s decision, dramatically reducing approval times
• Ethics review timeline: Initial IRB review typically takes 4-8 weeks for a complete submission. Expedited review is available for minimal-risk studies and protocol amendments
• Document requirements: The IRB requires the clinical protocol, investigator’s brochure, informed consent form (in Chinese), case report forms, investigator qualifications, and site GCP certification
• Informed consent focus: Chinese IRBs pay particular attention to the informed consent process, especially for vulnerable populations, genetic testing components, and compensation for trial-related injuries

2.4 Site Initiation and First Patient Enrollment (1-3 months)

The final phase before the trial becomes operational involves site-specific activities:

• Site qualification visit (SQV): The sponsor or CRO conducts a pre-study visit to verify site capabilities, patient population availability, and GCP compliance
• Site initiation visit (SIV): After IRB approval, the sponsor conducts a formal site initiation training session covering the protocol, procedures, data entry, and regulatory requirements
• Regulatory filing: The hospital’s GCP office must file the trial with provincial drug authorities (a notification requirement, not approval)
• Patient recruitment: The time to first patient enrolled depends on disease prevalence, site patient volume, and inclusion/exclusion criteria. For common diseases at major hospitals, first patient enrollment can occur within 2-4 weeks of SIV. For rare diseases or highly selective criteria, recruitment may take 2-6 months

3. Factors That Accelerate or Delay Approval

3.1 Factors That Accelerate Approval

• Breakthrough Therapy Designation (BTD): Drugs granted BTD by the CDE receive prioritized review with a target of 40 working days for IND review. The designation is available for drugs demonstrating substantial improvement over existing therapies for serious or life-threatening conditions
• Global simultaneous development: Drugs already approved or in late-stage development in the US, EU, or Japan may qualify for accelerated China review if the foreign data package demonstrates compelling safety and efficacy
• ICH-compliant dossier format: Submissions following ICH common technical document (CTD) format are reviewed more efficiently than non-standard formats. The CDE strongly prefers submissions in the eCTD format
• Pre-submission meeting: Sponsors who utilize the pre-submission meeting process typically experience 20-30% faster overall approval times because potential issues are identified and addressed before the formal submission
• Coprime review designation: For drugs addressing public health emergencies or rare pediatric diseases, the CDE may grant “coprime review” status, combining IND and NDA review into a single continuous process

3.2 Factors That Delay Approval

• Inadequate CMC data: The most common cause of CDE deficiency letters is incomplete or inadequate quality data, particularly for complex biologics. The CDE expects at least 6 months of stability data at submission, with real-time data preferred over accelerated stability data
• Insufficient bridging data: Foreign sponsors that rely entirely on foreign clinical data without adequate China-specific bridging studies face higher scrutiny
• HRML complications: Human Genetic Resource Management (HRML) approvals from the Ministry of Science and Technology (MOST) can add 3-6 months if not planned properly. The HRML application should be filed simultaneously with the IND submission to avoid sequential delays
• Translation quality issues: Poorly translated protocols, investigator brochures, or informed consent forms are rejected at the acceptance stage, causing delays before the review clock even starts
• Site qualification issues: Some hospitals may lack the necessary patient population, investigator expertise, or GCP infrastructure for complex trial designs, requiring site selection changes

4. Comparison: China vs. Other Major Markets

China’s timeline has improved substantially since the 2015 reforms, but it remains longer than the US and South Korea for standard applications. The gap narrows significantly for breakthrough therapies and priority-review drugs, where China’s timeline is competitive with other major markets.

5. Practical Strategies for Reducing Approval Timelines

5.1 Parallel Processing

The single most effective strategy for reducing total timeline is parallel processing of regulatory and ethics reviews. Foreign sponsors can prepare ethics committee submissions while the CDE review is ongoing, allowing IRB approval to be granted immediately after CDE approval rather than sequentially.

5.2 Early HRML Application

Human Genetic Resource Management (HRML) applications should be filed with MOST at least 3-6 months before the planned clinical trial start date. The application requires preparation of an International Cooperation Agreement and a detailed ethical review document. Engaging a specialized HRML consultant is strongly recommended.

5.3 CRO Selection

Selecting a contract research organization (CRO) with strong CDE relationships, established site networks, and a track record of successful IND submissions can significantly reduce timeline uncertainty. The top-tier CROs in China include IQVIA, LabCorp (Covance), Syneos, and Chinese CROs such as Tigermed, Hangzhou Tigermed, and PharmaLegacy.

5.4 Site Selection Optimization

Choosing sites with established GCP infrastructure, experienced investigators, and efficient IRB processes can save 1-2 months during the site initiation phase. Major teaching hospitals in Beijing (Peking Union Medical College Hospital, Beijing Cancer Hospital), Shanghai (Fudan-affiliated hospitals), and Guangzhou (Sun Yat-sen University Cancer Center) have the most streamlined processes.

6. 2026 Regulatory Developments Affecting Timelines

Several recent and anticipated regulatory changes will affect clinical trial approval timelines for foreign sponsors in 2026:

• eCTD mandate: The CDE now requires electronic Common Technical Document (eCTD) format for all IND submissions, replacing the earlier PDF-based system. The eCTD mandate has initially caused some submission delays as sponsors adapt to the new system, but is expected to accelerate review times once fully implemented
• Remote inspection expansion: The NMPA has formalized remote inspection procedures for foreign manufacturing facilities, reducing the scheduling delays associated with international travel. Remote inspections can typically be arranged within 4-6 weeks compared to 8-12 weeks for on-site inspections
• CTD format integration: The CDE is working toward full integration of its review system with ICH eCTD v4.0 standards, which will streamline cross-referencing and reduce the CDE’s internal processing time
• HRML online system: MOST has implemented an online portal for HRML applications that has reduced average processing times by 25-30% compared to the paper-based system it replaced

7. Conclusion

Clinical trial approval in China for foreign pharmaceutical companies takes approximately 5-8 months from IND submission to first patient enrolled under normal circumstances, with the CDE’s 60-working-day silent approval being the most predictable milestone. While this timeline is longer than the US FDA’s 30-day review period, China has made remarkable progress in reducing approval times from the 12-18 months that were standard before the 2015 reforms.

The key to minimizing approval timelines is careful preparation: engaging with the CDE through pre-submission meetings, submitting comprehensive and well-organized dossiers in eCTD format, filing HRML applications in parallel with the IND submission, and selecting experienced trial sites. Foreign sponsors that invest in these preparatory activities can reasonably expect to shave 2-3 months off the total timeline.